Lilly interested in ibogaine investments, its neuro leader says
Eli Lilly is interested in R&D efforts to “improve the profile of ibogaine,” the pharma giant’s neuroscience president said at a psychedelics conference Thursday. Carole Ho, who joined the company last year from Denali Therapeutics ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.